Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-04-2024 | Adalimumab | Case report

Adalimumab

Central nervous system demyelination

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Shirah B, et al. Adalimumab-induced central nervous system demyelination in a patient with rheumatoid arthritis. Neuroradiology Journal 37 : 234-236, No. 2, Apr 2023. Available from: URL: https://dx.doi.org/10.1177/19714009231173102
Metadata
Title
Adalimumab
Central nervous system demyelination
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55858-3

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Vandetanib

Case report

Trastuzumab

Case report

Methylprednisolone

Case report

Levosulpiride/risperidone

Case report

Furosemide

Case report

Multiple drugs